Known targets — ChEMBL curated mechanism
ACHECHKACHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNB1CHRNDCHRNECHRNGHRH2OPRM1
The experimentally established mechanism targets of Tetrabuthylammonium. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC22A1 | O15245 | 3/20 | 0.86 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.75 |
| ▸ | TP53 | P04637 | 1/20 | 0.75 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.75 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.75 |
| ▸ | TSHR | P16473 | 1/20 | 0.75 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.75 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.75 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.75 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.75 |
| ▸ | SLC22A2 | O15244 | 1/20 | 0.73 |
| ▸ | DNM1 | Q05193 | 7/20 | 0.63 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Tetrabuthylammonium SCHEMBL28382168 | 1.00 | SLC22A1 (0.86) | SLC22A1ALDH1A1TP53CYP3A4ALOX15 | |
| Tetrabuthylammonium SCHEMBL9229436 | 0.97 | SLC22A1 (0.80) | SLC22A1ALDH1A1TP53CYP3A4ALOX15 | |
| Tetrabuthylammonium SCHEMBL16418308 | 0.97 | SLC22A1 (0.80) | SLC22A1ALDH1A1TP53CYP3A4ALOX15 | |
| Tetrabuthylammonium SCHEMBL9468265 | 0.97 | SLC22A1 (0.80) | SLC22A1ALDH1A1TP53CYP3A4ALOX15 | |
| Tetrabuthylammonium SCHEMBL25266692 | 0.96 | SLC22A1 (0.92) | SLC22A1ALDH1A1TP53CYP3A4ALOX15 | |
| Tetrabuthylammonium SCHEMBL37661 | 0.96 | SLC22A1 (0.92) | SLC22A1ALDH1A1TP53CYP3A4ALOX15 | |
| Tetrabuthylammonium SCHEMBL19856400 | 0.96 | SLC22A1 (0.92) | SLC22A1ALDH1A1TP53CYP3A4ALOX15 | |
| Tetrabuthylammonium SCHEMBL12611195 | 0.96 | SLC22A1 (0.92) | SLC22A1ALDH1A1TP53CYP3A4ALOX15 | |
| Tetrabuthylammonium SCHEMBL1891 | 0.96 | SLC22A1 (0.92) | SLC22A1ALDH1A1TP53CYP3A4ALOX15 | |
| Tetrabuthylammonium SCHEMBL987324 | 0.96 | SLC22A1 (0.92) | SLC22A1ALDH1A1TP53CYP3A4ALOX15 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 40 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-118454731-A | For olefins CO2Catalyst for preparing cyclic carbonate by one-step method and preparation method thereof | 中国石油大学(华东) | 2024-08-09 | — | — | CN | disclosed |
| WO-2024089850-A1 | POLISHING LIQUID, POLISHING METHOD, COMPONENT MANUFACTURING METHOD, AND SEMICONDUCTOR COMPONENT MANUFACTURING METHOD | 株式会社レゾナック | 2024-05-02 | — | — | WO | disclosed |
| WO-2022126444-A1 | PATTERNED QUANTUM DOT FILM LAYER, QUANTUM DOT LIGHT-EMITTING DEVICE AND MANUFACTURING METHOD | 京东方科技集团股份有限公司 | 2022-06-23 | — | — | WO | disclosed |
| CN-100445282-C | Process for preparing 7-chloro-1-cyclopropyl-6-fluoro-4-oxo-1,4-dihydro-1,8-naphthyridine-3-carboxylic acid | LG LIFE SCIENCES LTD (KR) | 2008-12-24 | — | — | CN | disclosed |
| CN-101134793-A | Method for synthesizing completely biological degradable high-absorbent resin by anti-phase suspension polymerization | UNIV GUANGDONG TECHNOLOGY (CN) | 2008-03-05 | — | — | CN | disclosed |
| US-7326700-B2 | Cyclohexenyl phenyl carboxamides tocolytic oxytocin receptor antagonists | WYETH (US) | 2008-02-05 | — | — | US | disclosed |
| CN-1863802-A | Process for preparing 7-chloro-1-cyclopropyl-6-fluoro-4-oxo-1,4-dihydro-1,8-naphthyridine-3-carboxylic acid | LG LIFE SCIENCES LTD (KR) | 2006-11-15 | — | — | CN | disclosed |
| US-7109193-B2 | Tricyclic diazepines tocolytic oxytocin receptor antagonists | WYETH (US) | 2006-09-19 | — | — | US | disclosed |
| US-7064120-B2 | Tricyclic pyridyl carboxamides and derivatives thereof tocolytic oxytocin receptor antagonists | WYETH (US) | 2006-06-20 | — | — | US | disclosed |
| US-7022699-B2 | Cyclohexenyl phenyl diazepines vasopressin and oxytocin receptor modulators | WYETH (US) | 2006-04-04 | — | — | US | disclosed |
| US-20020198196-A1 | Novel cyclohexenyl phenyl diazepines vasopressin and oxytocin receptor modulators | WYETH | 2002-12-26 | — | — | US | disclosed |
| US-20020183311-A1 | Novel hydroxy cyclohexenyl phenyl carboxamides tocolytic oxytocin receptor antagonists | WYETH | 2002-12-05 | — | — | US | disclosed |
| WO-2002083684-A1 | NOVEL PYRIDINE- AND CYCLOHEXENYL-COMPRISING PYRROLOBENZODIAZEPI NE-CARBOXAMIDES AND DERIVATIVES THEREOF; TOCOLYTIC OXYTOCIN RECEPTOR ANTAGONISTS | WYETH (US) | 2002-10-24 | — | — | WO | disclosed |
| WO-2002083683-A1 | NOVEL TRICYCLIC PYRIDYL BENZAZEPINE CARBOXAMIDES AND DERIVATIVES THEREOF TOCOLYTIC OXYTOCIN RECEPTOR ANTAGONISTS | WYETH (US) | 2002-10-24 | — | — | WO | disclosed |
| WO-2002083679-A1 | NOVEL HYDROXY CYCLOHEXENYL PHENYL CARBOXAMIDES TOCOLYTIC OXYTOCIN RECEPTOR ANTAGONISTS | WYETH (US) | 2002-10-24 | — | — | WO | disclosed |
| WO-2002083678-A1 | TRICYCLIC DIAZEPINES AS TOCOLYTIC OXYTOCIN RECEPTOR ANTAGONISTS | WYETH (US) | 2002-10-24 | — | — | WO | disclosed |
| WO-2002083680-A1 | NOVEL TRICYCLIC HYDROXY CARBOXAMIDES AND DERIVATIVES THEREOF TOCOLYTIC OXYTOCIN RECEPTOR ANTAGONISTS | WYETH (US) | 2002-10-24 | — | — | WO | disclosed |
| WO-2002083681-A1 | NOVEL CYCLOHEXENYL PHENYL DIAZEPINES VASOPRESSIN AND OXYTOCIN RECEPTOR MODULATORS | WYETH (US) | 2002-10-24 | — | — | WO | disclosed |
| WO-2002083682-A1 | NOVEL 10-CYCLOHEXENYL-PHENYL PYRROLOBENZODIAZEPINE-3-CARBOXAMIDES AND DERIVATIVES THEREOF; TOCOLYTIC OXYTOCIN RECEPTOR ANTAGONISTS | WYETH (US) | 2002-10-24 | — | — | WO | disclosed |
| EP-0369398-A2 | Polyphosphazene derivatives containing carbonyl groups suitable for photoreticulation processes | CONSIGLIO NAZIONALE DELLE RICERCHE (IT) | 1990-05-23 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020183311-A1 | Novel hydroxy cyclohexenyl phenyl carboxamides tocolytic oxytocin receptor antagonists | OXTR, HTR1E, HTR3E | SLC22A1 3417/4885ALDH1A1 1197/4885TP53 4724/4885 |
| US-20020198196-A1 | Novel cyclohexenyl phenyl diazepines vasopressin and oxytocin receptor modulators | OXTR, AVPR2, AVPR1B | SLC22A1 3594/4885ALDH1A1 2776/4885TP53 4715/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.